Le Lézard
Classified in: Health
Subjects: WOM, TRI

New grant funds pilot study of female fertility decision tool for cancer survivors


MANHASSET, N.Y., Sept. 18, 2018 /PRNewswire/ -- Feinstein Institute for Medical Research Assistant Professor Catherine Benedict, PhD, has been awarded a five-year, $693,000 grant from the National Institutes of Health (NIH) to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children, make decisions and plan for the future. The new tool being created by Dr. Benedict and her team in the Center for Health Innovations and Outcomes Research has the potential to be a much-needed aid for the more than 400,000 young adult female cancer survivors currently living in the United States, many of whom hope to achieve parenthood someday.

Assistant Professor Catherine Benedict, PhD, received a $693,000 NIH grant to develop a web-based fertility decision-making tool for female cancer survivors.

Fertility is a central concern for many young survivors after treatment because many cancer therapies are associated with infertility issues and place women at greater risk for early menopause. In the first phase of her study, Dr. Benedict will work with a development team to build a web-based decision support and planning tool. The tool will be based off of data previously collected by Dr. Benedict, which examined how young women after cancer treatment made decisions regarding future family-building and the kind of support they wish they had when making those decisions.

"My research team found that even if young women make fertility plans before undergoing cancer treatment, they cannot implement their plan because of unexpected costs or being unsure if they will face menopause early," said Dr. Benedict. "With the NIH's support to build a web-based tool, patients will have access to information and options so they can tailor their own fertility plan."

The second phase of Dr. Benedict's study will allow female cancer survivors to use the tool in helping them make fertility decisions. Participants will then provide feedback and complete surveys to determine if the tool was helpful and whether it led to improved decision-making and lowered distress during the process. If the tool is found to be effective in supporting women through this process, larger clinical trials could follow and the tool could one day become a regular part of cancer care.

"Dr. Benedict's study is a great example showcasing how Feinstein Institute researchers can harness technology to improve the lives of patients," said Kevin J. Tracey, MD, president and CEO of the Feinstein Institute. "Her decision-making tool will assist patients and caregivers in making difficult medical decisions."

About the Feinstein Institute 
The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest health care provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the Feinstein Institute includes 4,000  researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine ? a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org

Contact: 
Heather E. Ball Mayer
516-465-7917
[email protected]

(PRNewsfoto/Northwell Health) (PRNewsfoto/Northwell Health)

SOURCE The Feinstein Institute for Medical Research


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: